EYP 002
Alternative Names: EYP002Latest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator ENYO Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Influenza-virus-infections in France (PO)
- 04 Dec 2017 ENYO Pharma plans to file an IND application with the US FDA in USA for Influenza virus infection by the end of 2018 (ENYO pharma pipeline, December 2017)
- 28 Nov 2017 Preclinical trials in Influenza virus infections in France (PO)